Navigation Links
Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
Date:3/26/2008

ents currently approved for these indications."

NuRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation retinoid and rexinoid compounds for application in oncology (treatment, prevention and adjunctive supportive therapy) and other highly prevalent diseases. The company's lead compounds are NRX4204, a highly specific, next-generation rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer and a RAR agonist for the treatment of acute leukemia. Based in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit http://www.nurxpharmaceutical.com.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this news release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the fact that the Company is engaged in early stage research and does not expect to obtain any revenues for several years and other risks as detailed from time to time in the Company's registration statement and reports and filings with the Securities and Exchange Commission. All forward-looking statements, if any, in this news release represent the Company's judgment as of the date of this news release. The Company disclaims, however, any intent or obligation to update forward-lookin
'/>"/>

SOURCE NuRx Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
2. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
3. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
4. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
5. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
6. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
7. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
10. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
11. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... LUXEMBOURG , May 17, 2013  ConvaTec today announced that it ... Ken Berger , CEO, and Ed Borkowski ... AM ET live via telephone. To participate in the ... (877) 366-0267. To participate in the conference call outside the ... The conference ID is 72195398. Participants should dial in ...
(Date:5/17/2013)... MIAMI LAKES, Fla. , May 17, 2013 ... products and delivery technology company that is developing new, patent-pending ... and minerals, announced today that it will hold a business ... on Wednesday, May 22 nd , 2013 at 4:30 PM ... Brian Tuffin will host the call and will ...
(Date:5/17/2013)... , May 17, 2013  Atossa Genetics, Inc. (NASDAQ: ... Kyle Guse , Chief Financial Officer & ... MicroCap Conference on Thursday, May 30, 2013, in ... The Company,s presentation is scheduled to begin ... live webcast. To access the webcast, go to www.atossagenetics.com ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3
(Date:5/19/2013)... 20, 2013 California has one of the ... employers are quickly discovering that comprehensive background checks are playing ... job. Driving records can paint an accurate ... that person has any DUI arrests, speeding offenses, and traffic ... are lining up to experience 4SafeDrivers.com, a new online service ...
(Date:5/19/2013)... new measure of the heterogeneity the variety of genetic ... treatment outcomes of patients with the most common type of ... of the journal Cancer , investigators at Massachusetts General ... their measure was a better predictor of survival than most ... squamous cell carcinoma of the head and neck. ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Cheap Concert ... his two concerts in Vegas in October will go on ... during the spring and summer months of 2013, this legendary ... , Whenever people hear “It’s Five O’clock Somewhere” ... voice of Jimmy Buffett inside their heads. Fortunately, fans can ...
(Date:5/19/2013)... A leading symptom of peripheral neuropathy, the ... end through natural ways, such as Neuracel’s Ultimate Support ... number of different underlying problems, the most commonly diagnosed ... is characterized by damage to the peripheral nerves in ... larger system, the peripheral nervous system. The peripheral nervous ...
(Date:5/19/2013)... HealthDay Reporter , , SATURDAY, May 18 (HealthDay News) ... Crohn,s disease overcome the fatigue and decreased muscle ... to new research. Extra vitamin D "was ... fatigue, greater quality of life and the ability ... Raftery, a research dietitian and doctoral candidate at ...
Breaking Medicine News(10 mins):Health News:4SafeDrivers.com Announces Driving Record Searches for California Employers 2Health News:Genetic diversity within tumors predicts outcome in head and neck cancer 2Health News:Genetic diversity within tumors predicts outcome in head and neck cancer 3Health News:Jimmy Buffett Las Vegas Tickets: Jimmy Buffett Tickets in Vegas at the MGM Grand on Oct. 19 and Oct. 26 Go on Public Sale Monday, May 20 at 10:00 a.m. Local Time 2Health News:Jimmy Buffett Las Vegas Tickets: Jimmy Buffett Tickets in Vegas at the MGM Grand on Oct. 19 and Oct. 26 Go on Public Sale Monday, May 20 at 10:00 a.m. Local Time 3Health News:Peripheral Neuropathy Naturally Treatable Through Neuracel's Ultimate Neuropathy Support System 2Health News:Extra Vitamin D May Ease Crohn's Symptoms, Study Finds 2Health News:Extra Vitamin D May Ease Crohn's Symptoms, Study Finds 3
... ARBOR, Mich., March 2 /PRNewswire/ -- The ... VHA Inc., the national healthcare alliance, as its preferred ... this preferred vendor designation, Thomson Reuters is authorized to ... members nationwide. Clinical Xpert has been named the KLAS ...
... OnlineHARRISBURG, Pa., March 2 United Concordia has enhanced ... tool and the service is now available online at ... a comprehensive redesign and now enables users to locate ... obtain driving directions to the dentist,s office. In addition ...
... the forthcoming 24th Annual EAU Congress in Stockholm (SE), the ... Studio. A first in the organisation,s annual congresses, EAU TV ... live in the EAU TV area at the congress venue ... start with a short introduction on the topic and continue ...
... one in every 2500 live births. Bones in the skulls ... of distressing developmental problems. Some of the affected children also ... Depending on the severity of their disease and its underlying ... a few days to as long as early adulthood. ...
... Reasons; Integrated Retention Strategy and Senior Management Commitment Are Necessary,to ... ... Orlando, FL (Vocus) March 2, 2009 -- Market ... bad news for health insurance providers. The good news: properly ...
... Health Care Associates, Inc. (MHA), the largest Alternate Site ... new website www.mhainc.com . The site was redesigned ... strong brand and leadership standing in the healthcare market. ... core businesses and supporting services, view current news announcements, ...
Cached Medicine News:Health News:VHA Selects Clinical Xpert from Thomson Reuters as its Preferred Solution for Mobile Clinical Improvement Systems 2Health News:VHA Selects Clinical Xpert from Thomson Reuters as its Preferred Solution for Mobile Clinical Improvement Systems 3Health News:United Concordia Dental Enhances Its Web-Based Find a Dentist Tool 2Health News:EAU TV goes 'live' at 24th Annual EAU Congress in Stockholm 2Health News:Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows 2Health News:Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows 3Health News:MHA Announces: Launch of New Website 2
... fully automated high-throughput glass-on-glass coverslipper. The ... microscope glass slides bearing tissue sections ... quality-grade coverslips of different standard sizes ... capability of handling a large variety ...
... mountant media dispensing system eliminates ... under the coverglass. All new ... most automated staining machines. Available ... pre-filled coverglass and mountant dispensers. ...
... Trellis Infusion Catheter enables the physician to ... fluid, and disperse the agent by means ... Trellis is a multi-lumen catheter with two ... and infusion holes located between these balloons. ...
ACRYSOF®, Posterior Chamber Intraocular Lenses are indicated for the replacement of the human lens to achieve visual correction of aphakia in patients sixty years and older. These lenses are i...
Medicine Products: